...
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging
【24h】

Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging

机译:人尿中的Kallidinogenase可通过缩短磁共振成像的平均通过时间来改善中风患者的预后

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Improving cerebral perfusion remains a good option for ischemic stroke for restoring cerebral blood flow. Human urinary kallidinogenase has been shown promising in treating stroke patients. To investigate whether human urinary kallidinogenase's efficacy in treating stroke patients has relationship with improving cerebral perfusion and possible mechanism. Methods: Fifty-eight stroke patients in Nanjing Drum Tower Hospital were enrolled in this prospective study. Of them, 29 received human urinary kallidinogenase, while the other 29 were selected as control. National institute health stroke scale, modified Rankin Scale and activities of daily living score were used to determine patient outcome. Cerebral perfusion in patients was determined by perfusion magnetic resonance imaging. Serum apelin and vascular endothelial growth factor were measured by enzyme-linked immunosorbent assay. Results: We confirmed that human urinary kallidinogenase improved stroke outcome in patients. Cerebral perfusion was elevated by human urinary kallidinogenase 12 days after therapy. Human urinary kallidinogenase enhanced vascular endothelial growth factor and APJ expression in stroke patients. The reduced mean transit time was related with favorable outcome analyzed by univariate logistic regression. Conclusions: Human urinary kallidinogenase facilitated stroke recovery and enhanced cerebral reperfusion through up-regulating vascular endothelial growth factor, apelin/APJ pathway.
机译:背景:改善脑灌注仍然是缺血性中风恢复脑血流的一个很好的选择。已经显示人尿激肽原酶在治疗中风患者中很有希望。目的探讨人尿中降钙素原酶在治疗中风患者中的功效是否与改善脑灌注和可能的机制有关。方法:本研究纳入了南京鼓楼医院的58例中风患者。其中,有29人接受了人尿中的尿激肽原酶,而其他29人被选为对照。美国国家卫生研究院健康卒中量表,改良的兰金量表和日常生活活动量表用于确定患者的预后。通过灌注磁共振成像确定患者的脑灌注。用酶联免疫吸附法测定血清apelin和血管内皮生长因子。结果:我们证实人尿中的尿激肽原酶可改善患者的中风预后。治疗后12天,人尿中的kallidinogenase增加了脑灌注。人尿中激肽原酶在中风患者中增强了血管内皮生长因子和APJ的表达。通过单因素逻辑回归分析,平均运输时间的减少与良好的结果相关。结论:人尿中激肽原酶通过上调血管内皮生长因子,apelin / APJ途径促进中风恢复并增强脑再灌注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号